The purpose of this study was to evaluate the clinical outcomes of
radiotherapy for patients with T1/T2 glottic
carcinoma. Patients with T1/T2 glottic
carcinoma histopathologically diagnosed with
squamous cell carcinoma and treated at our hospital between 2007 and 2015 were analyzed retrospectively. Our strategy for T1/T2 glottic
carcinoma was as follows:
radiotherapy alone with 2.25 Gy per fraction to a total of 25-28 fractions for patients with non-bulky T1 glottic
carcinoma;
concurrent chemoradiotherapy with oral S-1 and
radiotherapy with 2 Gy per fraction to a total of 30 fractions for patients with T1 bulky/T2 favorable glottic
carcinoma; or
chemoradiotherapy with high-dose
cisplatin and
radiotherapy with 2 Gy per fraction to a total of 35 fractions for T2 unfavorable glottic
carcinoma. Forty-eight patients were eligible. The median follow-up period among surviving patients was 38 months (range, 11-107). The disease was T1a in 23%, T1b in 13%, and T2 in 65% of patients. The 3-year local control rate in all patients, T1a, T1b, and T2 was 96.7%, 100%, 100%, and 96.0%, respectively. Of the 46 patients, one with T2 glottic
carcinoma developed recurrent disease at the primary site, and one with T2 glottic
carcinoma had lymph node recurrences in the neck. Acute Grade 3
dermatitis occurred in 8 (17%) patients and late Grade 2
hypothyroidism occurred in 2 (4%) patients. This retrospective study shows that our optimized treatment strategy of
radiotherapy depending on the stage of early glottic
carcinoma is not only effective but also well-tolerated.